SG Americas Securities LLC Has $75,000 Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

SG Americas Securities LLC raised its stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 102.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 116,748 shares of the company’s stock after purchasing an additional 59,182 shares during the period. SG Americas Securities LLC’s holdings in Lyell Immunopharma were worth $75,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Centiva Capital LP acquired a new position in shares of Lyell Immunopharma in the third quarter valued at about $31,000. Intech Investment Management LLC bought a new stake in Lyell Immunopharma during the third quarter worth about $52,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Lyell Immunopharma during the third quarter worth about $52,000. China Universal Asset Management Co. Ltd. lifted its position in Lyell Immunopharma by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 49,238 shares of the company’s stock worth $68,000 after purchasing an additional 19,287 shares during the period. Finally, Erste Asset Management GmbH bought a new stake in Lyell Immunopharma during the third quarter worth about $82,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently commented on LYEL shares. HC Wainwright reissued a “neutral” rating and issued a $1.00 target price on shares of Lyell Immunopharma in a report on Tuesday, November 12th. Bank of America lowered shares of Lyell Immunopharma from a “buy” rating to an “underperform” rating and dropped their price objective for the company from $6.00 to $1.00 in a report on Wednesday, October 30th.

Lyell Immunopharma Stock Performance

NASDAQ:LYEL opened at $0.58 on Friday. The company has a market capitalization of $170.04 million, a PE ratio of -0.74 and a beta of -0.35. The company has a 50 day simple moving average of $0.64 and a two-hundred day simple moving average of $1.03. Lyell Immunopharma, Inc. has a fifty-two week low of $0.51 and a fifty-two week high of $3.26.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.